Study on miR-582-5p in Cisplatin-Resistant Cervical Cancer Cell Line Hela/DDP
Abstract
every year. Cisplatin is the first-line chemotherapy drug for cervical cancer. Studies have shown that approximately 20% of cervical cancer
patients become resistant to chemotherapy, resulting in decreased efficacy, tumor recurrence, and poor prognosis. Therefore, the study of the
mechanism of cisplatin resistance in cervical cancer cells was the basis of this study. Objective: To establish a cisplatin-resistant cervical
cancer cell line Hela/DDP and to investigate the differential expression of miR-582-5p in HeLa and Hela/DDP cell lines. Methods: Cervical
cancer cell line Hela was cultured and cisplatin-resistant cancer cell line Hela/DDP was established. The expression of miR-582-5p was detected and compared by RT-qPCR. Results: The IC50 of Hela/DDP cells was 60.91 ng/mL, the IC50 of Hela cells was 9.88 ng/mL(P?0.05),
and the resistance index RI value was 6.16. Compared with HeLa cells, the expression of miR-582-5p in HeLa/DDP cells was lower (P?0.05).
Conclusion: The expression of miR-582-5p was downregulated in cisplatin-resistant cervical cancer cell lines, and the low expression of
miR-582-5p may be related to cisplatin resistance in cervical cancer.
Keywords
Full Text:
PDFReferences
[1] Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2024. 74(3): p. 229-263.
[2] Kumar, L., et al., Chemotherapy and targeted therapy in the management of cervical cancer. 2018. 42(2): p. 120-128.
[3] Zhu, H., et al., Molecular mechanisms of cisplatin resistance in cervical cancer. 2016: p. 1885-1895.
[4] Hill, M., N.J.D.m. Tran, and mechanisms, miRNA interplay: mechanisms and consequences in cancer. 2021. 14(4): p. dmm047662.
[5] Ali Syeda, Z., et al., Regulatory mechanism of MicroRNA expression in cancer. 2020. 21(5): p. 1723.
[6] Chen, Y., et al., MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting
PRKCD. 2014. 320(1): p. 12-20.
[7] Chen, Y., et al., microRNA-499a promotes the progression and chemoresistance of cervical cancer cells by targeting SOX6. 2020. 25: p.
205-216.
[8] Liu, Q., S. Liu, and D.J.A.-C.D. Wang, Overexpression of microRNA-21 decreased the sensitivity of advanced cervical cancer to chemoradiotherapy through SMAD7. 2020. 31(3): p. 272-281.
[9] Huang, D. and C.J.O.l. Li, circ-ACACA promotes proliferation, invasion, migration and glycolysis of cervical cancer cells by targeting
the miR-582-5p/ERO1A signaling axis. 2021. 22(5): p. 795.
[10] Zhao, T., et al., Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer.
Evid Based Complement Alternat Med, 2022. 2022: p. 6019975.
[11] Hussen, B.M., et al., MicroRNA: A signature for cancer progression. 2021. 138: p. 111528.
[12] Huang, S., et al., miR-582-3p and miR-582-5p suppress prostate cancer metastasis to bone by repressing TGF-? signaling. 2019. 16: p.
91-104.
[13] Li, L. and L.J.S.J.o.B.S. Ma, Upregulation of miR-582-5p regulates cell proliferation and apoptosis by targeting AKT3 in human endometrial carcinoma. 2018. 25(5): p. 965-970.
[14] Hu, Y., et al., LINC00641/miR-582-5p mediate oxaliplatin resistance by activating autophagy in gastric adenocarcinoma. 2020. 10(1): p.
14981.
[15] Xiao, W., et al., miR-582-5p inhibits migration and chemo-resistant capabilities of colorectal cancer cells by targeting TNKS2. 2022.
44(6): p. 747-756.
DOI: http://dx.doi.org/10.70711/pmr.v2i5.6718
Refbacks
- There are currently no refbacks.
